The prominent role of CTM journal solute carrier family in pancreatic cancer

Although the incidence of pancreatic cancer is low, less than 2.
5% in the population, the mortality rate of pancreatic cancer is very high, and the five-year survival rate is less than 8%
.

Pancreatic cancer ranks seventh in cancer-related deaths worldwide
.

According to GLOBOCAN statistics, there were 458918 (2.
5%) newly diagnosed pancreatic cancer patients worldwide in 2018, and 432242 (4.
5%) pancreatic cancer patients died
.

But because the pancreas is located deep in the abdomen, patients with pancreatic cancer usually have no typical symptoms
.

Because there is still a lack of accurate and early diagnosis of pancreatic cancer, many patients with pancreatic cancer are already in the middle-advanced stage or have already metastasized when they are first diagnosed
.

Therefore, only 15-20% of pancreatic cancer patients are suitable for surgical resection after initial diagnosis
.


Although there have been great advances in the diagnosis, perioperative treatment, radiotherapy and systemic treatment of pancreatic cancer in recent years, these advances have not greatly improved the overall survival rate of pancreatic cancer patients
.

Therefore, the study of the molecular mechanism of pancreatic cancer is the key to the study of pancreatic oncology
.

Because solute carriers (SLCs) are targets of chemotherapeutic drugs or mediators of drug deposition, SLCs are a hot spot in cancer pharmacology and drug development
.

Since it was discovered that SLC39A4 has a significant effect on the growth of pancreatic malignant tumors, the author's team has also conducted in-depth research on the role of SLCs in pancreatic cancer
.


On March 23, 2021, the Journal of Clinical and Translational Medicine published the latest review "Emerging roles of the solute carrier family in pancreatic cancer" [6] (